DEF: PAVmed Seeks Reverse Stock Split to Maintain Nasdaq Listing

PAVmed Inc. will hold a special meeting on December 5, 2025, to seek stockholder approval for a reverse stock split and a reduction in authorized common stock to regain Nasdaq compliance and attract institutional investors.

Summary

• A special meeting of stockholders will be held on December 5, 2025, to vote on two proposals: a reverse stock split and an adjournment proposal.
• The Reverse Split Proposal seeks to amend the company's certificate of incorporation to effect a reverse stock split of common stock at a ratio between 1-for-10 and 1-for-30, to be determined by the Board.
• The proposal also includes an associated reduction in authorized common stock from 250,000,000 shares to 25,000,000 shares.
• The primary reason for the reverse split is to increase the per share trading price of the common stock to regain compliance with Nasdaq's minimum $1 bid price requirement.
• The company received a Nasdaq delisting notice on January 23, 2025, and did not regain compliance within the initial 180-day period, receiving an extension until January 19, 2026.
• The Board also believes the reverse split will make the common stock more attractive to a broader range of institutional and other investors.
• Approval of the Reverse Split Proposal requires the affirmative vote of a majority of outstanding capital stock and common stock entitled to vote.
• The effectuation of the Reverse Split is conditioned on obtaining consent from the holder of the Series C Preferred Stock.
• The Adjournment Proposal allows for the Special Meeting to be adjourned if there are insufficient votes to approve the Reverse Split Proposal.

Sentiment

Score: 3

Explanation: The filing addresses a critical issue (Nasdaq delisting) with a proposed solution (reverse stock split). However, the necessity of this action, the failure to meet prior compliance deadlines, and the inherent risks associated with reverse splits (e.g., potential for further price decline, dilution) indicate a negative underlying situation. The company is taking steps to mitigate a severe risk, but it's a reactive measure to a poor performance indicator.

Positives

• Aims to regain compliance with Nasdaq's minimum bid price requirement, preventing potential delisting.
• Intends to make the common stock more attractive to a broader range of institutional and professional investors, who often have policies against investing in low-priced stocks.
• The reduction in authorized common stock, while absolute, may increase the number of shares authorized for issuance relative to outstanding shares, providing flexibility for future business needs such as equity awards, financing, acquisitions, or strategic partnerships.

Negatives

• The company failed to regain Nasdaq compliance within the initial 180-day period (by July 22, 2025) after receiving a delisting notice on January 23, 2025.
• The current closing bid price of $0.4292 as of October 23, 2025, is significantly below the Nasdaq minimum of $1.
• There is no assurance that the reverse split will increase the per share trading price as expected or that it will be maintained above the $1 minimum.
• The reverse split may decrease the liquidity of the common stock due to a reduced number of outstanding shares.
• The reverse split will increase the number of stockholders owning 'odd lots' (fewer than 100 shares), which generally incur higher brokerage commission and transaction costs.
• Future issuances of common stock under existing arrangements (options, warrants, convertible securities, equity plans) or future financings will dilute existing stockholders.

Risks

• Cannot assure that the reverse split will increase the per share trading price of the common stock as expected or that it will have the desired effects.
• The per share trading price of the common stock may decline from the proportionately adjusted price promptly after the reverse split.
• The per share trading price of the common stock may decrease in the future due to factors unrelated to the reverse split, such as financial results, market conditions, and market perception.
• Even if compliance with Nasdaq's minimum bid price requirement is regained, there is no assurance that the company will remain in compliance with this or other continued listing requirements (e.g., minimum stockholders' equity, public float, market value of public float).
• The reverse split may decrease the liquidity of the common stock, particularly if the increased per share trading price is not maintained.
• The reverse split will increase the number of stockholders who own odd lots, leading to potentially higher transaction costs.
• Future issuances of common stock by the company, including under outstanding options, warrants, preferred stock, convertible notes, and equity compensation plans, may have an adverse effect on the market price of the common stock and dilute existing stockholders.

Future Outlook

The Board expects the reverse split to increase the per share trading price of the common stock and make it more attractive to institutional investors. However, there is no assurance that these intended benefits will materialize, or that the per share trading price will not decrease in the future due to other factors. The company has no current agreement or commitment to issue additional shares of common stock, except for existing derivative securities and equity compensation plans, but explores opportunities for strategic transactions and equity capital raises. The company does not anticipate paying cash dividends in the foreseeable future, expecting to retain earnings to finance business growth.

Management Comments

• The Board believes that it is in the best interest of the company's stockholders to effect the Reverse Split in order to increase the per share trading price of the common stock.
• The Board approved the Reverse Split in an effort to increase the closing bid price of the common stock to the level required for continued listing on Nasdaq.
• The Board believes that the Reverse Split will make the common stock more attractive to a broader range of institutional and other investors.
• The Board does not intend for the Reverse Split to be the first step in a series of plans or proposals to effect a going private transaction.
• The company does not anticipate paying dividends in the foreseeable future but expects to retain earnings to finance the growth of its business.

Industry Context

The need for a reverse stock split to maintain a Nasdaq listing is a common occurrence for companies whose stock price has fallen below the minimum bid requirement. This situation often indicates underlying challenges in company performance or market perception, making it difficult to attract broader investment. Many institutional investors and brokerage firms have internal policies against investing in or recommending low-priced stocks, which can further exacerbate liquidity issues and hinder capital formation. This action is a reactive measure to address a compliance issue rather than a proactive strategic growth initiative.

Comparison to Industry Standards

• Nasdaq Listing Rule 5550(a)(2) requires a minimum bid price of $1 per share for continued listing on the Nasdaq Capital Market. PAVmed's stock price of $0.4292 as of October 23, 2025, is significantly below this standard, necessitating the proposed reverse split.
• The company's situation is comparable to other small-cap or development-stage companies that face delisting threats due to low stock prices, often leading them to pursue reverse stock splits as a compliance measure.
• The stated goal of attracting institutional investors is a common objective for companies seeking to improve their market profile, as many institutions have internal policies restricting investment in stocks below a certain price threshold (e.g., $5 or $10).

Corporate Governance

Related Party Transactions

• Lishan Aklog, M.D. (Chairman and CEO) is deemed to have voting and dispositive power over shares held by Pavilion Venture Partners LLC and HCFP/AG LLC.
• Dana Carrera may be deemed to beneficially own shares held by Tasso Capital, LLC.
• Ayrton Capital LLC and Waqas Khatri may be deemed to beneficially own shares held by Alto Opportunity Master Fund, SPC Segregated Master Portfolio B, which holds convertible notes and Series C Preferred Stock.

Stakeholder Impact

• **Shareholders**: Will own a reduced number of shares with a proportionately higher per-share price. Face risks of further stock price decline, reduced liquidity, and dilution from future equity issuances. Fractional shares will be rounded up to a whole share.
• **Institutional Investors**: The reverse split aims to make the stock more attractive to this group by increasing the per-share price, potentially removing barriers to investment.
• **Preferred Stockholders (Series C)**: Their consent is required for the reverse split, and their conversion rights will be proportionately adjusted.
• **Option/Warrant Holders**: The conversion rate, per share exercise price, and number of shares issuable upon exercise or conversion of outstanding derivative securities will be proportionately adjusted.
• **Employees**: Equity compensation plans (2014 Plan, ESPP) will have proportionate adjustments to the number of shares reserved for issuance and exercise prices of awards.

Next Steps

• Stockholders will vote on the Reverse Split Proposal and the Adjournment Proposal at the Special Meeting on December 5, 2025.
• If approved, the Board will determine the specific reverse split ratio (between 1-for-10 and 1-for-30).
• The company must obtain the consent of the holder of its Series C Preferred Stock for the reverse split to be effective.
• If approved and implemented, the company will file a certificate of amendment with the Delaware Secretary of State promptly after the Special Meeting.
• The company aims to regain Nasdaq compliance by January 19, 2026, by maintaining a closing bid price of at least $1 for a minimum of ten consecutive business days.

Key Dates

Recommendation

The company is taking a necessary, albeit reactive, step to address a critical Nasdaq listing compliance issue, which is essential for its continued public trading. While the reverse stock split aims to increase the per-share price and attract institutional investors, it does not address the underlying operational or financial performance that led to the low stock price. There are significant risks that the stock price may not sustain its post-split level or that further dilution could occur. Investors should hold to observe if the company successfully regains and maintains Nasdaq compliance and, more importantly, demonstrates improved business fundamentals and strategic execution to justify a higher valuation. A 'buy' would be premature given the inherent risks and lack of immediate positive operational news, and a 'sell' might be an overreaction if the compliance issue is resolved and the company's long-term prospects remain viable.

Keywords

PAVMED, PAVM, Reverse Stock Split, Nasdaq Compliance, Delisting Risk, Proxy Statement, Stockholder Meeting, Corporate Governance, Equity Dilution, Capital Market, Preferred Stock, Common Stock